 |
Adam Bonislawski is the editor of GenomeWeb's ProteoMonitor. He covers proteomics and life science mass spectrometry. E-mail Adam Bonislawski and follow his GenomeWeb Twitter account at @ProteoMonitor. |
Vermillion's Q1 Revenues Decline 28 Percent, CEO Page Stepping Down
May 18, 2012
Vermillion's Q1 Revenues Decline 28 Percent, CEO Page Stepping Down
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- UPDATE: Vermillion Repays Quest $5.9M, Ending Companies' Credit Agreement
October 19, 2012 / ProteoMonitor - Vermillion Posts 11 Percent Rise in 2012 Revenues, 8 Percent Uptick in OVA1 Sales
February 22, 2013 / ProteoMonitor - Vermillion Shareholders File Suit Challenging Elimination of Board Seat
June 15, 2012 / ProteoMonitor - Vermillion Planning Layoffs, Seeking New Partnerships in 2012
January 6, 2012 / ProteoMonitor - Vermillion Buys Correlogic's Assets for $435K; Correlogic Settles with LabCorp, Quest
November 11, 2011 / ProteoMonitor